search results for

refine results

sort by


result type


Press Releases

FDA: Eli Lilly drug reduces cardiovascular death

Shares of Eli Lilly gains momentum on news of an FDA drug approval. CNBC's Seema Mody reports.


Bringing foreign drugs into the US market is a dangerous concept: Merck CEO

CNBC’s Meg Tirrell talks to Kenneth Frazier, Merck CEO, at the fifth annual Forbes Healthcare Summit in New York about the future of drug pricing under the Trump administration as well as Alzheimer’s research.


Drug bust hits healthcare stocks

The "Fast Money" traders weigh in on Eli Lilly and Juno Therapeutics, following failed drug trials.


Still upside in Eli Lilly despite drug failure: Divan

Vamil Divan, Credit Suisse senior analyst, discusses Eli Lilly's failed Alzheimer's drug trial and the effect on its stock price.


Analyst on LLY: In general, I believe Biogen drug is better

Ronny Gal, Bernstein senior analyst, weighs in on Eli Lilly's failed Alzheimer's drug study results.


Eli Lilly & Juno Therapeutics plummet after failed drug trials

The “Fast Money Halftime Report” traders weigh in on the biotech sector, with Eli Lilly and Juno Therapeutics stocks dropping significantly.


Stocks to Watch: November 23, 2016

Eli Lilly, Urban Outfitters and Alphabet stocks are making headlines this Wednesday morning.


Lilly Alzheimer's drug does not slow memory loss: Study

Lilly shares tumble after its Alzheimer drug study did not meet its goals, reports CNBC's Meg Tirrell. Obviously we are disappointed but we remain committed to Alzheimer's disease, says John Lechleiter, Eli Lilly CEO. And David Ricks, Eli Lilly incoming CEO, weighs in on the company's future growth prospects.


Eli Lilly may react strongly to Alzheimer's drug trial

CNBC's Meg Tirrell reports on Eli Lilly's Alzheimer's drug trial plans and speaks to incoming CEO David Ricks.


Eli Lilly's new approach for Alzheimer's

CNBC's Meg Tirrell reports on Eli Lilly's drug being tested to treat Alzheimer's disease.